drug
Zyclara
Marketedupdated 5mo agoby Bausch Health US LLC
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying Zyclara
- phase1A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas
- phase3Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face
- phase2Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma
- phase1A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
- phase3Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions
- phase4Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%
- phase4Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients Treated with Imiquimod
- phase2Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 18, 2029
~2.9 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (10)
- Apr 30, 2030method-of-use (U-1455)US 109186353.6y
- Apr 30, 2030method-of-use (U-172)US 112027523.6y
- Apr 30, 2030method-of-use (U-172)US 118502453.6y
- Dec 11, 2029method-of-use (U-68)US 102386443.2y
- Dec 11, 2029method-of-use (U-68)US 113181303.2y
- Dec 11, 2029method-of-use (U-68)US 82222703.2y
- Dec 11, 2029method-of-use (U-68)US 82368163.2y
- Dec 11, 2029method-of-use (U-68)US 82991093.2y
- Aug 18, 2029method-of-use (U-1455)US 102386452.9y
- Aug 18, 2029method-of-use (U-1455)US 85981962.9y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that